AI English summary of an SEC filing — figures as filed

The company said Chief Commercial Officer Everett Cunningham notified it on January 4, 2026 that he will resign, with the resignation effective January 16, 2026.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Jan 8, 2026Period of report Jan 8, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said Chief Commercial Officer Everett Cunningham notified it on January 4, 2026 that he will resign, with the resignation effective January 16, 2026.
Illumina said it appointed Eric D. Green, M.D., Ph.D., as Chief Medical Officer, effective February 2, and that he will report to the CEO.
The company said Dr. Green spent more than 30 years at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health, served as NHGRI Director from 2009 to 2025, and will join the Executive Leadership Team.
Illumina said Cunningham is leaving to become CEO of a life science tools company. Jacob Thaysen, CEO, will serve as interim chief commercial officer until a permanent successor is named.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Everett Cunningham Steps Down as Chief Commercial Officer

The company said Chief Commercial Officer Everett Cunningham notified it on January 4, 2026 that he will resign, with the resignation effective January 16, 2026.

Source · Based on the filing body and exhibits

Illumina Appoints Eric D. Green as Chief Medical Officer

Illumina said it appointed Eric D. Green, M.D., Ph.D., as Chief Medical Officer, effective February 2, and that he will report to the CEO.

Source · Based on the filing body and exhibits

Green's Career and Executive Leadership Team Role

The company said Dr. Green spent more than 30 years at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health, served as NHGRI Director from 2009 to 2025, and will join the Executive Leadership Team.

Source · Based on the filing body and exhibits

Thaysen to Serve as Interim CCO Until Successor Named

Illumina said Cunningham is leaving to become CEO of a life science tools company. Jacob Thaysen, CEO, will serve as interim chief commercial officer until a permanent successor is named.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.